Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial
Journal of Clinical Neurology
;
: 27-32, 2010.
Article
in English
| WPRIM
| ID: wpr-57291
ABSTRACT
BACKGROUND AND PURPOSE:
Frovatriptan is a selective 5-HT1B/1D agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients.METHODS:
In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate.RESULTS:
Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2 hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%, p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient.CONCLUSIONS:
These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Oxalates
/
Thorax
/
Carbazoles
/
Tryptamines
/
Incidence
/
Asian People
/
Headache
/
Migraine Disorders
Type of study:
Controlled clinical trial
/
Incidence study
/
Prognostic study
Limits:
Adult
/
Humans
Language:
English
Journal:
Journal of Clinical Neurology
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS